Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""

Project description

Redefining cardiac monitoring: a non-invasive approach to stent surveillance

Every year, millions of patients with coronary implanted stents face the risk of a malfunction that can lead to a heart attack, often with fatal consequences. Traditional diagnostic methods rely on invasive procedures, leaving patients vulnerable until symptoms emerge. The EIC-funded NIMBLE System project addressed these challenges by harnessing microwave technology to develop the world's first non-invasive, real-time monitoring of coronary stent function during routine clinical visits. This innovative approach enables early intervention, shifting healthcare from reactive to proactive. Currently in advanced stages of development, NIMBLE's results in pre-clinical trials and ongoing human testing signal a major step forward in patient care. With support from the EIC Accelerator program, NIMBLE aims to revolutionise implant diagnostics, potentially saving millions of lives worldwide.

Objective

At NIMBLE Diagnostics we are developing a first-in-class microwave-based medical device for the non-invasive and non-ionizing monitoring of patients with implanted stents.
Stents are one of the most implanted devices worldwide and are used to re-open blocked arteries and restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but, after implantation, become blocked or damaged in 30% of cases. Symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence of serious complications, including strokes, heart attacks or sudden death.
Diagnosis of malfunctioning stents is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex, costly and invasive procedure is not appropriate for ongoing monitoring, which is why the standard of care only reacts when patients already have potentially life-threatening symptoms.
The NIMBLE System can read the electromagnetic signature of any stent non-invasively in less than 5 seconds and can be used to provide information on stent status and malfunction during regular clinical visits. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of therapy, shifting from reactive to proactive care.
Our technology is currently at TRL5/6, with an MVP that has shown excellent results in pre-clinical validations. We have also started the first-in-human testing in a pilot study of 30 patients that will finish early 2024.
The EIC Accelerator program will allow us to bridge the biggest risk of our project by performing the regulatory clinical trial to obtain the CE mark, as well as support us to create and access a multi-billion blue ocean market opportunity. This will allow us to establish NIMBLE as a European leader in the future of implant diagnostics and aid millions of patients worldwide.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

NIMBLE DIAGNOSTICS SL
Net EU contribution
€ 2 306 500,00
Address
CR CANYET SENSE NUMERO
08916 BADALONA
Spain
SME
Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 295 000,00